Positron emission tomography (PET) with 18 F-dopa has long been regarded as the gold standard for measuring the integrity of dopaminergic nerve terminals and for assessing disease severity in PD patients. 1,2 18 F-Dopa, a fluorinated analogue of L-dopa, follows the same presynaptic dopamine (DA) synthesis pathway, is decarboxylated by aromatic L-amino acid decarboxylase (AADC) and stored in presynaptic vesicles as 18 F-labeled dopamine, thus providing an in vivo measurement of AADC activity and presynaptic DA storage capacity. 3, 4 Postmortem and in vivo analysis of the human PD brain has revealed that striatal 18 F-dopa uptake correlates positively with nigral cell count 5 and negatively with motor symptomatology. [6] [7] [8] [9] [10] [11] [12] However, upregulation of AADC activity as a compensatory response to progressive DA cell death may result in 18 F-dopa overestimating nerve terminal density in early PD. 9, [13] [14] [15] In addition, the AADC enzyme acts as a decarboxylation catalyst within the biosynthetic pathways of several other monoamine neurotransmitters, 15, 16 within which AADC upregulation is also thought to occur. 15, 17, 18 Given that most AADCcontaining neurons are capable of taking up and converting 18 F-dopa, 15, 17, [19] [20] [21] any alterations cannot be attributed solely to dopamine terminal dysfunction.
Other nuclear imaging studies in PD patients have used radioligands that bind to the dopamine transporter (DAT). DATs are exclusively located on dopaminergic neurons, 22 and experimental work in animal models of PD have demonstrated a close relationship between striatal DA concentration, presynaptic DAT, and nigrostriatal cell loss. 23 Thus, in contrast to AADC, DAT appears to represent a more appropriate and specific marker for studying the integrity of striatal dopaminergic innervation, although it must be noted that possible compensatory DAT downregulation may cause its underestimation. 13 The negative association between striatal DAT and motor severity is well documented using a number of DAT radioligands developed for use with PET and SPECT 24, 25 including those most commonly used in studies of PD, 123 I-b-CIT and its fluoropropyl analogue 123 I-FP-CIT. 10, 11, [26] [27] [28] [29] [30] However, these radioligands also have an affinity for the serotonin (SERT) and noradrenaline (NET) transporters, 31, 32 the former of which is substantially present in the human striatum, [33] [34] [35] which complicates their use as measures of PD progression.
Significant striatal AADC and DAT declines have consistently been demonstrated in several longitudinal studies using the above ligands, yet, interestingly, changes over time do not appear to correlate with changes in motor symptomatology, 1, [36] [37] [38] [39] [40] and findings from several clinical trials demonstrated incongruity between drug-related changes in motor performance and changes in striatal 18 F-dopa 41, 42 and 123 I-b-CIT 43, 44 values. Given that the serotonergic and noradrenergic systems also undergo disease-related neurodegeneration in PD, 15, 17, 18, [45] [46] [47] it is possible that a lack of specificity for the DA system may result in tracer values reflecting a composition of monoaminergic degeneration including nondopaminergic factors not directly associated with motor symptoms.
The current study directly compared the validity of AADC and DAT as biological targets for the assessment of motor severity and rate of progression in early PD patients at baseline and after 19 months of followup. To estimate DAT, we used 11 C-PE2I, a highly specific DAT radioligand that has been shown to have at least 17.5-fold greater DAT/SERT and 20-fold greater DAT/NET selectivity than b-CIT 31, 32, 48 and negligible competition with maprotiline and citalopram. [49] [50] [51] In humans, 11 C-PE2I specific to nonspecific binding is highest in the striatum and is in agreement with the known DAT distribution postmortem, 52, 53 and its utility for differential diagnostics has recently been demonstrated. 54 Thus, we hypothesized that striatal DAT density, as measured using 11 C-PE2I, would show stronger associations with motor severity compared with AADC activity derived using 18 F-dopa PET.
Methods Subjects
Thirty-three patients with idiopathic PD were included from the FP7 EC Transeuro program cohort (http://www.transeuro.org.uk/; also see Supplementary Materials 1). Of these, 23 were rescanned 18.8 6 3.4 months later, hereafter referred to as the PD FU subgroup. All patients satisfied Queen Square Brain Bank criteria for PD diagnosis. 55 Motor severity was assessed by 2 experienced raters using the motor subscore of the Unified Parkinson's Disease Rating Scale (UPDRS-III) 56, 57 and the Hoehn and Yahr scale 58 in the practically defined off-medicated state (see Supplementary Table 1 ). Patients were excluded for dementia (Mini-Mental State Examination score < 26), atypical or secondary parkinsonism, and standard MRI exclusion criteria such as the presence of metallic implants and pregnancy. Demographic information can be seen in Table 1 .
MRI and PET Procedure
All scans were conducted at Imanova (Hammersmith Hospital, London). A high-resolution volumetric T1-weighted magnetization-prepared rapid acquisition gradient-echo scan was obtained on a 3T Siemens Magnetom Trio system to aid PET registration (MPRAGE: TR, 2300 milliseconds; TE, 2.98 milliseconds; flip angle, 98; time to inversion, 900 milliseconds; GRAPPA acceleration factor PE, 2; slice thickness, 1 mm; FoV, 240 3 25 6 mm; matrix size, 240 3 256 mm). One whole-brain volume was acquired consisting of 160 slices lasting 301 seconds. F-dopa, 180 MBq) were prepared to 10 mL using saline solution and administered intravenously as single bolus injections followed immediately by a 10-mL saline flush. Administration was at 1 mL/s. Dynamic emission data were acquired continuously for 90 minutes postinjection, then reconstructed into 26 temporal frames using a filtered back-projection algorithm (direct inversion Fourier transform; matrix size, 128 3 128; zoom, 2.6; 5 mm transaxial Gaussian filter; pixel size, 2 mm isotropic). A low-dose CT transmission scan (0.36 mSv) was acquired for attenuation correction. Patients withdrew dopaminergic medication 24 hours prior to scanning for standard release and 48 hours for prolonged release preparations. For 
Image Preprocessing
PET and MRI images were preprocessed and analyzed using MIAKAT v3.4.2. (Molecular Imaging and Kinetic Analysis Toolbox, Imanova Ltd., London, UK), 59 which uses FSL (FMRIB Image Analysis Group, Oxford, UK), 60 SPM (Statistical Parametric Mapping, Wellcome Trust Centre for Neuroimaging, London, UK), and in-house preprocessing and kinetic modeling procedures and implemented in MATLAB (Mathworks, Natick, MA).
Structural MPRAGE images were brain-extracted, segmented, and rigid-body-registered to the Montreal Neurological Institute (MNI) template. 61 MPRAGE images were then used to manually trace striatal regions of interest (bilateral/left/right caudate, anterior and posterior putamen) on the axial plane followed by trace checks on the coronal plane, using Analyze 11.0 (Biomedical Imaging Resource, Mayo Clinic). The putamen was subdivided based on the anterior commissure landmark. 62 The cerebellum was defined by nonlinearly registering the MNI template to MPRAGE The UPDRS and H&Y scale were assessed in the practically defined off-medication state. For the PD FU subgroup, Wilcoxon signed rank and paired t-tests were used to assess the difference between baseline and follow-up.
and applying the deformation fields to an MNI-based regional atlas (CIC Atlas v1.2; GlaxoSmithKline Clinical Imaging Centre, London, UK). 62 Rigid-body registration parameters were applied to the gray-and white-matter segmentation images to enable automatic masking of cerebellar gray matter.
Dynamic PET images were corrected for intrascan head movement using frame-to-frame rigid registration (reference frame, 16) and summed (10-90 minutes) to obtain signal-averaged (ADD) images. ADD images were coregistered to the corresponding structural MPRAGE using normalized mutual information and resultant matrices applied to the realigned dynamic PET frames so that all images were in register. Region-of-interest (ROI) maps were then overlaid onto the dynamic PET frames to obtain regional timeactivity curves. For 11 C-PE2I, the simplified reference tissue model was used to calculate regional nondisplaceable binding potential (BP ND ). 63 Cerebellar gray matter was used as a reference as it has been shown to have negligible DAT density compared with other brain regions.
49,50,52 For
18
F-dopa, the regional influx constant (K i ) was calculated using the Patlak graphical method 64 between 30 and 90 minutes (t* 5 30). AADC activity in both the cerebellum and occipital cortex is assumed to be zero, 65 thus a cerebellar reference was used to maintain analytical consistency across radioligands.
Parametric images were also generated by fitting kinetic models at each voxel of the MPRAGEregistered dynamic PET series. To enable voxel-wise statistical analysis at the group level, registered grayand white-matter segments were used to create a study-specific template using diffeomorphic anatomical registration through exponentiated Lie algebra (DAR-TEL), which was then normalized (affine transform) to MNI space in SPM12. Individual flow fields and normalization parameters were then applied to the corresponding parametric images while preserving concentrations to ensure PET voxel values were not modulated for volumetric changes.
ROI Analysis
All statistical analyses were performed using SPSS v22.0 (SPSS Statistics for Macintosh; IBM Corp., Armonk, NY).
Pearson's correlation coefficient was used to evaluate the relationship between bilateral striatal 18 F-dopa K i and 11 C-PE2I BP ND measures and UPDRS-III, tremor, and bradykinesia-rigidity subscores (see Supplementary Table 1 ) for all PD patients at baseline. Correlations between lateralized UPDRS-III, tremor, and bradykinesia-rigidity subscores (clinically most/ least affected [MA/LA] sides) and contralateral PET measures were assessed using Spearman's rho, as several lateralized variables demonstrated significant deviation from normality (Shapiro-Wilk P < 0.05). Differences between lateralized correlation coefficients were tested using Steiger's Z procedure. 
Voxel-Wise Analysis
Because PD is a highly asymmetric movement disorder, MRI and PET images for patients with more severe clinical features on the right side were leftright-flipped prior to image preprocessing. Normalized parametric images for all PD patients at baseline (n 5 33) were then entered into a multiple regression model in SPM12 with UPDRS-III, tremor, and bradykinesiarigidity subscores as covariates of interest and age and sex as nuisance covariates. For follow-up analysis (n 5 23), difference maps created by voxel-wise subtraction (D: follow-up -baseline) were entered into a multiple regression model with DUPDRS-III, Dtremor, and Dbradykinesia-rigidity subscores as covariates of interest and age at baseline and sex as nuisance covariates. An explicit mask was applied to limit the analysis to the basal ganglia. Statistical inference was based on threshold-free cluster enhancement (TFCE toolbox v89 for SPM8/SPM12, http://dbm.neuro.uni-jena.de/ tfce/), which uses a nonparametric permutation testing approach (5000 permutations) to produce images in which voxel-wise values are reflective of the local spatial extent and negates the need to define arbitrary initial cluster-forming thresholds. 67 Voxel-wise statistical maps were corrected for family-wise error at P FWE < 0.1.
Results

ROI Analysis
Baseline At baseline, 18 F-dopa K i showed significant negative correlations with UPDRS-III and bradykinesia-rigidity in the posterior putamen (Fig. 1a,c) . In contrast, 11 C-PE2I BP ND showed significant negative relationships with both UPDRS-III and bradykinesia-rigidity in all striatal ROIs (Fig. 1b,d) . No significant correlations were found between 18 F-dopa K i and 11 C-PE2I BP ND and tremor subscores.
Multiple regression analyses showed that all models significantly predicted UPDRS-III and bradykinesiarigidity scores. However, only 
Follow-Up
For the PD FU subgroup, the Wilcoxon signed rank test showed a significant decrease in anterior Significant negative correlations were found between change in motor severity (DUPDRS-III; Dbradykinesiarigidity) and D
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C-PE2I BP ND in the caudate and posterior putamen (Fig. 1f,h ). In the anterior putamen, D
C-PE2I BP ND significantly correlated with Dbradykinesiarigidity; however, the correlation with DUPDRS-III did not survive Benjamini-Hochberg FDR. No significant correlations were evident between D 18 F-dopa K i and change in motor severity measures in any striatal ROI (Fig. 1e,g ). Correlations between D
C-PE2I BP ND and DUPDRS-III in the caudate (Z 5 1.885, P < 0.05) and anterior putamen (Z 5 1.984, P < 0.05) and between D 11 C-PE2I BP ND and Dbradykinesia-rigidity in the caudate (Z 5 2.028, P < 0.05) and anterior putamen (Z 5 2.49, P < 0.01) were significantly stronger the than corresponding D
18
F-dopa K i correlations (Fig. 1e-h ).
Voxel-Wise Analysis
For 18 F-dopa K i , 2 small clusters showed a negative correlation with UPDRS-III score in the posterior and anterior putamen on the most affected side (P FWE < 0.1). The association with bradykinesia-rigidity subscore revealed slightly larger clusters in the most affected posterior putamen (P FWE < 0.05) and caudate body (P FWE < 0.1). For 11 C-PE2I BP ND , clusters showing significant negative correlations with UPDRS-III score were found in the most affected putamen and caudate (P FWE < 0.05) and posterior putamen on the least affected side (P FWE < 0.1). Negative correlations with bradykinesia-rigidity subscores revealed 2 large clusters on both the most affected side(P FWE 5 0.002) and the least affected side (P FWE 5 0.005), which encompassed the putamen and caudate and extended into the ventral portion of the striatum (Fig. 2a-d , Table 3 ). Voxel-wise analysis of the difference maps (D: follow-up -baseline) revealed a single cluster in the most affected putamen showing a significant negative correlation between D 11 C-PE2I BP ND and Dbradykinesia-rigidity (P FWE 5 0.042); see Figure 2e and Table 3 . No other significant results were found for longitudinal analysis. There were no regions showing positive correlations between 18 F-dopa K i , 11 C-PE2I BP ND , and motor severity measures. No significant clusters were found for tremor.
Discussion
Our findings are in agreement with previous studies showing an inverse relationship between striatal 18 F-dopa K i and motor severity. 2, 6, [8] [9] [10] [11] However, we found that negative correlations between motor severity and striatal 11 C-PE2I BP ND were overall stronger than the analogous 18 F-dopa K i correlations. This was further evidenced when tracers were compared directly in a multiple regression analysis, whereby 11 C-PE2I BP ND proved to be more predictive of motor severity between patients than 18 F-dopa K i . In addition, although voxel-wise analysis revealed significant clusters in both cases, at baseline the spatial extent was greater for 11 C-PE2I BP ND than for 18 F-dopa K i , encompassing the majority of the putamen bilaterally and the most affected caudate. At follow-up, only the most affected putamen showed a relationship between changes in 11 C-PE2I BP ND in bradykinesia-rigidity.
Taken together, the data suggest that DAT quantification using 11 C-PE2I BP ND is more sensitive for investigating disease progression than 18 F-dopa K i . Although negative correlations have consistently been found between striatal presynaptic DAT density and motor severity using a number of tropane analogues 10, 11, 13, [26] [27] [28] [29] [30] 68, 69 few have directly compared the validity of AADC and DAT imaging as biomarkers relating to the progression of disease in human PD patients. Both Eshuis et al (2006) 10 and Ishikawa et al (1996) 11 found equivalently strong relationships for 
I-FP-CIT and 18 F-dopa with motor severity, whereas, interestingly, another study noted that the correlation with the DAT radioligand 76 Br-FE-CBT was weaker than with 18 F-dopa. 9 It is possible that the differing results could be explained by the variation in affinities of DAT tracers for SERT, which, although predominantly concentrated in the raphe and thalamus, are also located in the striatum. [33] [34] [35] We are unable to comment on 76 Br-FE-CBT because, to our knowledge, there are no available studies describing its binding characteristics. However, autoradiographic and in vivo data indicate significant binding decreases in known SERT regions after administration of selective serotonin reuptake inhibitors (SSRI) for b-CIT, FP-CIT, and FE-CIT, 70, 71 with b-CIT analogue comparison studies demonstrating DAT-to-SERT selectivity ratios of 1.68, 2.78, and 3.6, respectively. 31, 32 Because serotonergic degeneration in PD is thought to follow a variable nonlinear progression 72 and is not associated with disease severity, 46 ligands with relatively low DAT-to-SERT selectivity may result in an underestimation of the association between DAT and motor severity when the influence of SERT is not accounted for. In contrast, some studies reported that PE2I may have up to 29.4 times greater selectivity for DAT over SERT. C-PE2I BP ND ) was assessed using difference maps (D, follow-up -baseline) of the PD FU subgroup (n 5 23) also showed negative clusters after correcting for age at baseline and sex (threshold-free cluster enhancement corrected at P FWE < 0.1) (e). No clusters showing positive correlations were identified. An explicit mask was applied to limit statistical analysis to the striatum. Cluster maps were overlaid onto a study-specific average template created using DARTEL in MNI coordinate space. MA, most affected side; LA, least affected side. [Color figure can be viewed at wileyonlinelibrary.com] PE2I appears to be unaltered by SSRI competition, 49, 50 and 1 study directly comparing striatal 123 I-PE2I and 123 I-FP-CIT binding found no significant change by citalopram infusion for the former but a 24% decrease for the latter. 51 Our findings may reflect this selectivity difference, although it should be noted that we did not directly compare 11 C-PE2I with other DAT ligands in the current study.
We observed that longitudinal changes in motor severity were not associated with changes in 18 F-dopa uptake, replicating previous findings. 36, 39, 40 In contrast, changes in motor severity were related to changes in 11 C-PE2I binding, suggesting that motor progression is more closely correlated to striatal DAT decline than to AADC activity. Other longitudinal studies using 123 I-b-CIT SPECT to quantify alterations in DAT density over time have previously failed to demonstrate this relationship with motor progression. 37, 38 The current results could therefore be explained by differing serotonergic and noradrenergic contributions to tracer signal. There is also evidence to suggest that AADC activity is upregulated in early PD as a compensatory mechanism for the loss of DA nerve terminals. 9, [13] [14] [15] In theory, this would result in 18 F-dopa underestimating the rate of dopaminergic neurodegeneration, which in turn could potentially confound associations with symptom severity. However, it is worth noting that DAT downregulation is also hypothesized to occur to maintain substantial DA levels in the synapse, 13 which could similarly affect the symptomatic relationships with 11 C-PE2I, albeit through overestimating the rate of denervation.
Nonetheless, other 18 F-dopa PET studies examining extrastriatal alterations in early PD have identified additional increases in regions known to possess high concentrations of serotonergic and noradrenergic neurons, such as the raphe complex and locus coeruleus, 15, 17, 18 indicating that AADC upregulation is not restricted solely to dopaminergic neurons. The ubiquitous availability of AADC and its upregulation across monoaminergic neurons constitute a bias away from accurate estimation of DA-specific progression, which to some degree may perturb the relationship between 18 F-dopa and motor severity. In our longitudinal cohort, we observed a trend toward a lesser annual decline rate for 18 F-dopa as compared with 11 C-PE2I (see Supplementary Table 2) , which would lend partial support to this theory. However, we caution that evidence for this mismatch was not statistically strong, and it is possible that a delay of approximately 18 months was not enough to afford adequate power for robust detection. A greater understanding could be gained by further repeated measurements and/or extending the length of time between examinations.
Our results have important implications for the use of molecular imaging to monitor the progression of underlying PD pathology. Of particular interest is their potential for providing objective indices on the rate of nigrostriatal degeneration in clinical trials involving novel drug treatments and neuroprotective and neuromodulatory therapies. Several double-blind, randomized, controlled trials utilizing I-b-CIT signals 31, 32, 48, 70, 73 makes it difficult to attribute druginduced striatal changes to modifications of the dopaminergic system alone.
11
C-PE2I has limitations; the short half-life of 11 C essentially restricts its use to centers with in-house production facilities, 54 and the requirement that scanning time be >70 minutes to reliably estimate striatal DAT 75 may increase head movement and patient discomfort. In addition, its test-retest variability has been shown to be approximately double that of 18 F-dopa (4.52% vs 9.8% in the striatum), 75, 76 which makes changes in the short-term more difficult to detect and restricts its case-by-case application. However, the ability of 11 C-PE2I to track changes in motor performance over time, as demonstrated here, and its favorable DAT selectivity [48] [49] [50] [51] 73 illustrates its potential as an alternative surrogate biomarker for studies of PD progression.
In conclusion, we have shown that striatal DAT density, as measured using 11 C-PE2I, has greater predictive value and sensitivity for detecting differences in motor severity in early-moderate PD patients than AADC imaging using 18 F-dopa. Furthermore, our results indicate that DAT decline is closely associated with motor progression over time, whereas no such relationship was found with AADC. These findings provide further evidence of the utility of 11 C-PE2I as an objective biomarker for investigating the effects of novel interventions on the rate of nigrostriatal degeneration in PD.
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